Diagnosis and treatment of schizotypal personality disorder: evidence from a systematic review

Sophie K Kirchner, Astrid Roeh, Jana Nolden, Alkomiet Hasan, Sophie K Kirchner, Astrid Roeh, Jana Nolden, Alkomiet Hasan

Abstract

The main objective of this review was to evaluate studies on the diagnosis, treatment, and course of schizotypal personality disorder and to provide a clinical guidance on the basis of that evaluation. A systematic search in the PubMed/MEDLINE databases was conducted. Two independent reviewers extracted and assessed the quality of the data. A total of 54 studies were eligible for inclusion: 18 were on diagnostic instruments; 22, on pharmacological treatment; 3, on psychotherapy; and 13, on the longitudinal course of the disease. We identified several suitable and reliable questionnaires for screening (PDQ-4+ and SPQ) and diagnosing (SIDP, SIDP-R, and SCID-II) schizotypal personality disorder. Second-generation antipsychotics (mainly risperidone) were the most often studied drug class and were described as beneficial. Studies on the longitudinal course described a moderate remission rate and possible conversion rates to other schizophrenia spectrum disorders. Because of the heterogeneity of the studies and the small sample sizes, it is not yet possible to make evidence-based recommendations for treatment. This is a systematic evaluation of diagnostic instruments and treatment studies in schizotypal personality disorder. We conclude that there is currently only limited evidence on which to base treatment decisions in this disorder. Larger interventional trials are needed to provide the data for evidence-based recommendations.

Conflict of interest statement

In the past 5 years, A.H. received a paid speakership from Desitin, Otsuka, Janssen-Cilag, and Lundbeck. He was previously member of an advisory boards of Roche, Otsuka, Lundbeck, and Janssen-Cilag. The authors declare no competing interests.

References

    1. Raine A. Schizotypal personality: neurodevelopmental and psychosocial trajectories. Annu. Rev. Clin. Psychol. 2006;2:291–326. doi: 10.1146/annurev.clinpsy.2.022305.095318.
    1. Fonseca-Pedrero E, et al. The structure of schizotypal personality traits: a cross-national study. Psychol. Med. 2018;48:451–462. doi: 10.1017/S0033291717001829.
    1. Kwapil TR, Barrantes-Vidal N, Silvia PJ. The dimensional structure of the Wisconsin Schizotypy Scales: factor identification and construct validity. Schizophr. Bull. 2008;34:444–457. doi: 10.1093/schbul/sbm098.
    1. Kwapil TR, Gross GM, Silvia PJ, Raulin ML, Barrantes-Vidal N. Development and psychometric properties of the Multidimensional Schizotypy Scale: a new measure for assessing positive, negative, and disorganized schizotypy. Schizophr. Res. 2018;193:209–217. doi: 10.1016/j.schres.2017.07.001.
    1. Mason OJ. The assessment of schizotypy and its clinical relevance. Schizophr. Bull. 2015;41(Suppl 2):S374–S385. doi: 10.1093/schbul/sbu194.
    1. Meehl PE. Schizotaxia, schizotypy, schizophrenia. Arch. Gen. Psychiatry. 1962;46:935–944. doi: 10.1001/archpsyc.1989.01810100077015.
    1. Meehl PE. Toward an integrated theory of schizotaxia. J. Pers. Disord. 1990;4:1–99. doi: 10.1521/pedi.1990.4.1.1.
    1. Lenzenweger MF. Schizotypy, schizotypic psychopathology and schizophrenia. World Psychiatry. 2018;17:25–26. doi: 10.1002/wps.20479.
    1. Chapman LJ, et al. Impulsive nonconformity as a trait contributing to the prediction of psychotic-like and schizotypal symptoms. J. Nerv. Ment. Dis. 1984;172:681–691. doi: 10.1097/00005053-198411000-00007.
    1. Kwapil TR, Barrantes-Vidal N. Schizotypy: looking back and moving forward. Schizophr. Bull. 2015;41(Suppl 2):S366–S373. doi: 10.1093/schbul/sbu186.
    1. Ettinger U, Meyhofer I, Steffens M, Wagner M, Koutsouleris N. Genetics, cognition, and neurobiology of schizotypal personality: a review of the overlap with schizophrenia. Front. Psychiatry. 2014;5:18. doi: 10.3389/fpsyt.2014.00018.
    1. Fonseca-Pedero EDM. Schizotypal traits and psychotic-like experiences during adolescence: an update. Psicothema. 2017;29:5–17.
    1. Fanous AH, et al. Significant correlation in linkage signals from genome-wide scans of schizophrenia and schizotypy. Mol. Psychiatry. 2007;12:958–965. doi: 10.1038/sj.mp.4001996.
    1. Walter EE, Fernandez F, Snelling M, Barkus E. Genetic consideration of schizotypal traits: a review. Front. Psychol. 2016;7:1769. doi: 10.3389/fpsyg.2016.01769.
    1. Gaebel W, Zielasek J, Cleveland HR. Classifying psychosis--challenges and opportunities. Int. Rev. Psychiatry. 2012;24:538–548. doi: 10.3109/09540261.2012.737313.
    1. World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines (World Health Organization, 2016) .
    1. Pulay AJ, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV schizotypal personality disorder: results from the wave 2 national epidemiologic survey on alcohol and related conditions. Prim. Care. Companion J. Clin. Psychiatry. 2009;11:53–67. doi: 10.4088/PCC.08m00679.
    1. Rosell DR, Futterman SE, McMaster A, Siever LJ. Schizotypal personality disorder: a current review. Curr. Psychiatry Rep. 2014;16:452. doi: 10.1007/s11920-014-0452-1.
    1. Sobin C, et al. Evidence of a schizotypy subtype in OCD. J. Psychiatr. Res. 2000;34:15–24. doi: 10.1016/S0022-3956(99)00023-0.
    1. Kendler KS, et al. A longitudinal twin study of cluster A personality disorders. Psychol. Med. 2015;45:1531–1538. doi: 10.1017/S0033291714002669.
    1. Bilder RM, et al. Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol. Psychiatry. 2002;52:701–707. doi: 10.1016/S0006-3223(02)01416-6.
    1. Nyegaard M, et al. CACNA1C (rs1006737) is associated with schizophrenia. Mol. Psychiatry. 2010;15:119–121. doi: 10.1038/mp.2009.69.
    1. Hodgkinson CA, et al. Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am. J. Hum. Genet. 2004;75:862–872. doi: 10.1086/425586.
    1. Debbane M, et al. Developing psychosis and its risk states through the lens of schizotypy. Schizophr. Bull. 2015;41(Suppl 2):S396–S407. doi: 10.1093/schbul/sbu176.
    1. Herpertz SC, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J. Biol. Psychiatry. 2007;8:212–244. doi: 10.1080/15622970701685224.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 2009;151:264–269. doi: 10.7326/0003-4819-151-4-200908180-00135.
    1. Jacobsberg LB, Hymowitz P, Barasch A, Frances AJ. Symptoms of schizotypal personality disorder. Am. J. Psychiatry. 1986;143:1222–1227. doi: 10.1176/ajp.143.10.1222.
    1. Widiger TA, Frances A, Warner L, Bluhm C. Diagnostic criteria for the borderline and schizotypal personality disorders. J. Abnorm. Psychol. 1986;95:43–51. doi: 10.1037/0021-843X.95.1.43.
    1. McGlashan TH. Testing DSM-III symptom criteria for schizotypal and borderline personality disorders. Arch. Gen. Psychiatry. 1987;44:143–148. doi: 10.1001/archpsyc.1987.01800140045007.
    1. Vaglum P, Friis S, Vaglum S, Larsen F. Comparison between personality disorder diagnoses in DSM-III and DSM-III-R: reliability, diagnostic overlap, predictive validity. Psychopathology. 1989;22:309–314. doi: 10.1159/000284612.
    1. Handest P, Parnas J. Clinical characteristics of first-admitted patients with ICD-10 schizotypal disorder. Br. J. Psychiatry Suppl. 2005;48:s49–s54. doi: 10.1192/bjp.187.48.s49.
    1. Perry JC, O’Connell ME, Drake R. An assessment of the schedule for schizotypal personalities and the DSM-III criteria for diagnosing schizotypal personality disorder. J. Nerv. Ment. Dis. 1984;172:674–680. doi: 10.1097/00005053-198411000-00006.
    1. Stangl D, Pfohl B, Zimmerman M, Bowers W, Corenthal C. A structured interview for the DSM-III personality disorders. A preliminary report. Arch. Gen. Psychiatry. 1985;42:591–596. doi: 10.1001/archpsyc.1985.01790290073008.
    1. Raine A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr. Bull. 1991;17:555–564. doi: 10.1093/schbul/17.4.555.
    1. Battaglia M, Cavallini MC, Macciardi F, Bellodi L. The structure of DSM-III-R schizotypal personality disorder diagnosed by direct interviews. Schizophr. Bull. 1997;23:83–92. doi: 10.1093/schbul/23.1.83.
    1. Merritt RD, Balogh DW, Kok CJ. DSM-IV Cluster A personality disorder diagnoses among young adults with a 2-7-8 MMPI profile. Assessment. 1998;5:273–285. doi: 10.1177/107319119800500307.
    1. Fossati A, et al. Latent class analysis of DSM-IV schizotypal personality disorder criteria in psychiatric patients. Schizophr. Bull. 2001;27:59–71. doi: 10.1093/oxfordjournals.schbul.a006860.
    1. Dickey CC, et al. Clinical, cognitive, and social characteristics of a sample of neuroleptic-naive persons with schizotypal personality disorder. Schizophr. Res. 2005;78:297–308. doi: 10.1016/j.schres.2005.05.016.
    1. Morey LC, Benson KT, Skodol AE. Relating DSM-5 section III personality traits to section II personality disorder diagnoses. Psychol. Med. 2016;46:647–655. doi: 10.1017/S0033291715002226.
    1. Sanislow CA, et al. Confirmatory factor analysis of DSM-IV borderline, schizotypal, avoidant and obsessive-compulsive personality disorders: findings from the Collaborative Longitudinal Personality Disorders Study. Acta Psychiatr. Scand. 2002;105:28–36. doi: 10.1034/j.1600-0447.2002.0_479.x.
    1. McGlashan TH. Recovery style from mental illness and long-term outcome. J. Nerv. Ment. Dis. 1987;175:681–685. doi: 10.1097/00005053-198711000-00006.
    1. Axelrod SR, Grilo CM, Sanislow C, McGlashan TH. Schizotypal Personality Questionnaire-Brief: factor structure and convergent validity in inpatient adolescents. J. Pers. Disord. 2001;15:168–179. doi: 10.1521/pedi.15.2.168.19219.
    1. Ryder AG, Costa PT, Bagby RM. Evaluation of the SCID-II personality disorder traits for DSM-IV: coherence, discrimination, relations with general personality traits, and functional impairment. J. Pers. Disord. 2007;21:626–637. doi: 10.1521/pedi.2007.21.6.626.
    1. Fossati A, et al. Taxonic structure of schizotypal personality disorder: a multiple-instrument, multi-sample study based on mixture models. Psychiatry Res. 2005;137:71–85. doi: 10.1016/j.psychres.2005.02.008.
    1. Matsui M, Sumiyoshi T, Niu L, Kurokawa K, Kurachi M. Minnesota Multiphasic Personality Inventory profile characteristics of schizotypal personality disorder. Psychiatry Clin. Neurosci. 2002;56:443–452. doi: 10.1046/j.1440-1819.2002.01034.x.
    1. Baer L, et al. Effect of axis II diagnoses on treatment outcome with clomipramine in 55 patients with obsessive-compulsive disorder. Arch. Gen. Psychiatry. 1992;49:862–866. doi: 10.1001/archpsyc.1992.01820110026003.
    1. Goldberg SC, et al. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch. Gen. Psychiatry. 1986;43:680–686. doi: 10.1001/archpsyc.1986.01800070070009.
    1. Goldberg SC, Schulz SC, Resnick RJ, Hamer RM, Schulz PM. Differential prediction of response to thiothixene and placebo in borderline and schizotypal personality disorders. Psychopharmacol. Bull. 1987;23:342–346.
    1. Kirrane RM, Mitropoulou V, Nunn M, Silverman J, Siever LJ. Physostigmine and cognition in schizotypal personality disorder. Schizophr. Res. 2001;48:1–5. doi: 10.1016/S0920-9964(00)00059-1.
    1. Koenigsberg HW, et al. Risperidone in the treatment of schizotypal personality disorder. J. Clin. Psychiatry. 2003;64:628–634. doi: 10.4088/JCP.v64n0602.
    1. McClure MM, et al. The effects of guanfacine on context processing abnormalities in schizotypal personality disorder. Biol. Psychiatry. 2007;61:1157–1160. doi: 10.1016/j.biopsych.2006.06.034.
    1. McClure MM, et al. Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. Neuropsychopharmacology. 2010;35:1356–1362. doi: 10.1038/npp.2010.5.
    1. McClure MM, et al. The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder. J. Clin. Psychopharmacol. 2009;29:396–398. doi: 10.1097/JCP.0b013e3181accfd9.
    1. Rabella M, et al. Neurophysiological evidence of impaired self-monitoring in schizotypal personality disorder and its reversal by dopaminergic antagonism. Neuroimage Clin. 2016;11:770–779. doi: 10.1016/j.nicl.2016.05.019.
    1. Rosell DR, et al. Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology. 2015;40:446–453. doi: 10.1038/npp.2014.192.
    1. Siegel BV, et al. D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder. Schizophr. Res. 1996;20:29–32. doi: 10.1016/0920-9964(95)00002-X.
    1. Serban G, Siegel S. Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am. J. Psychiatry. 1984;141:1455–1458. doi: 10.1176/ajp.141.11.1455.
    1. Hymowitz P, Frances A, Jacobsberg LB, Sickles M, Hoyt R. Neuroleptic treatment of schizotypal personality disorders. Compr. Psychiatry. 1986;27:267–271. doi: 10.1016/0010-440X(86)90001-5.
    1. Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res. 2000;96:91–98. doi: 10.1016/S0165-1781(00)00203-1.
    1. Keshavan M, Shad M, Soloff P, Schooler N. Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophr. Res. 2004;71:97–101. doi: 10.1016/j.schres.2003.12.008.
    1. Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am. J. Psychiatry. 1991;148:1064–1067. doi: 10.1176/ajp.148.8.1064.
    1. Rybakowski JK, Drozdz W, Borkowska A. Low dose risperidone in the treatment of schizophrenia-like symptoms in high-risk subjects. J. Clin. Psychopharmacol. 2003;23:674–675. doi: 10.1097/01.jcp.0000095352.32154.e1.
    1. Di Lorenzo R, et al. Aripiprazole: effectiveness and safety under naturalistic conditions. Exp. Clin. Psychopharmacol. 2007;15:569–575. doi: 10.1037/1064-1297.15.6.569.
    1. Gutkovich Z, Rosenthal RN, Bogdonoff L. Transient psychosis with psychogenic polydipsia in schizotypal patient taking fluoxetine. Psychosomatics. 1998;39:295–296. doi: 10.1016/S0033-3182(98)71349-0.
    1. Heiden A, de Zwaan M, Frey R, Presslich O, Kasper S. Paroxetine in a patient with obsessive-compulsive disorder, anorexia nervosa and schizotypal personality disorder. J. Psychiatry Neurosci. 1998;23:179–180.
    1. Poyurovsky M. Clozapine in treatment-refractory obsessive-compulsive disorder with comorbid schizotypal personality disorder. Isr. J. Psychiatry Relat. Sci. 2008;45:219–220.
    1. Zwier KJ, Rao U. Buspirone use in an adolescent with social phobia and mixed personality disorder (cluster A type) J. Am. Acad. Child Adolesc. Psychiatry. 1994;33:1007–1011. doi: 10.1097/00004583-199409000-00011.
    1. Nordentoft M, et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr. Res. 2006;83:29–40. doi: 10.1016/j.schres.2006.01.002.
    1. Karterud S, et al. Day hospital therapeutic community treatment for patients with personality disorders. An empirical evaluation of the containment function. J. Nerv. Ment. Dis. 1992;180:238–243. doi: 10.1097/00005053-199204000-00005.
    1. McKay D, Neziroglu F. Social skills training in a case of obsessive-compulsive disorder with schizotypal personality disorder. J. Behav. Ther. Exp. Psychiatry. 1996;27:189–194. doi: 10.1016/0005-7916(96)00010-9.
    1. Plakun EM, Burkhardt PE, Muller JP. 14-year follow-up of borderline and schizotypal personality disorders. Compr. Psychiatry. 1985;26:448–455. doi: 10.1016/0010-440X(85)90081-1.
    1. McGlashan TH. Schizotypal personality disorder. Chestnut Lodge follow-up study: VI. Long-term follow-up perspectives. Arch. Gen. Psychiatry. 1986;43:329–334. doi: 10.1001/archpsyc.1986.01800040039006.
    1. Modestin J, Foglia A, Toffler G. Comparative study of schizotypal and schizophrenic patients. Psychopathology. 1989;22:1–13. doi: 10.1159/000284574.
    1. Mehlum L, et al. Personality disorders 2-5 years after treatment: a prospective follow-up study. Acta Psychiatr. Scand. 1991;84:72–77. doi: 10.1111/j.1600-0447.1991.tb01423.x.
    1. Bender DS, et al. Treatment utilization by patients with personality disorders. Am. J. Psychiatry. 2001;158:295–302. doi: 10.1176/appi.ajp.158.2.295.
    1. Grilo CM, et al. Two-year stability and change of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. J. Consult. Clin. Psychol. 2004;72:767–775. doi: 10.1037/0022-006X.72.5.767.
    1. Warner MB, et al. The longitudinal relationship of personality traits and disorders. J. Abnorm. Psychol. 2004;113:217–227. doi: 10.1037/0021-843X.113.2.217.
    1. McGlashan TH, et al. Two-year prevalence and stability of individual DSM-IV criteria for schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders: toward a hybrid model of axis II disorders. Am. J. Psychiatry. 2005;162:883–889. doi: 10.1176/appi.ajp.162.5.883.
    1. Bernstein DP, et al. Prevalence and stability of the DSM-III-R personality disorders in a community-based survey of adolescents. Am. J. Psychiatry. 1993;150:1237–1243. doi: 10.1176/ajp.150.8.1237.
    1. Olin SS, et al. Childhood behavior precursors of schizotypal personality disorder. Schizophr. Bull. 1997;23:93–103. doi: 10.1093/schbul/23.1.93.
    1. Asarnow JR. Childhood-onset schizotypal disorder: a follow-up study and comparison with childhood-onset schizophrenia. J. Child Adolesc. Psychopharmacol. 2005;15:395–402. doi: 10.1089/cap.2005.15.395.
    1. Woods SW, et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr. Bull. 2009;35:894–908. doi: 10.1093/schbul/sbp027.
    1. Farooq, S., et al. Pharmacological interventions for schizotypal personality disorder. Cochrane Database Syst. Rev. CD009047 (2011).

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe